Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Roche”

A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple SclerosisActive Not Recruiting
NCT07008378Phase 1Updated Jul 15, 2026
Sponsor: Genentech, Inc.
Multiple Sclerosis
United States
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung CancerActive Not Recruiting
NCT03456076Phase 3Updated Jul 15, 2026
Sponsor: Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
United States, Australia, Austria, Belarus, Bosnia and Herzegovina +22 more
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Active Not Recruiting
NCT05123703Phase 3Updated Jul 15, 2026
Sponsor: Hoffmann-La Roche
Relapsing-remitting Multiple Sclerosis
United States, Argentina, Australia, Austria, Belgium +20 more
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)Recruiting
NCT06780150N/AUpdated Jul 15, 2026
Sponsor: Hoffmann-La Roche
Multiple Sclerosis
Germany, Switzerland
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionActive Not Recruiting
NCT04661150Phase 2Updated Jul 15, 2026
Sponsor: Hoffmann-La Roche
Gastric Cancer · Gastroesophageal Junction Adenocarcinoma
China
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia ARecruiting
NCT07226206Phase 1, Phase 2Updated Jul 14, 2026
Sponsor: Hoffmann-La Roche
Hemophilia A
United States
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 DiabetesRecruiting
NCT07670416Phase 3Updated Jul 14, 2026
Sponsor: Hoffmann-La Roche
Obesity · Overweight · Type 2 Diabetes Mellitus (T2DM)
China
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseRecruiting
NCT07181109Phase 3Updated Jul 13, 2026
Sponsor: Alnylam Pharmaceuticals
High Risk Cardiovascular Disease · Hypertension · High Cardiovascular Risk
United States, Argentina, Australia, Austria, Belgium +29 more
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin LymphomaRecruiting
NCT05169515Phase 1Updated Jul 13, 2026
Sponsor: Hoffmann-La Roche
Non-Hodgkin Lymphoma
United States, Israel, Italy, Spain, United Kingdom
A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's DiseaseRecruiting
NCT07298421Phase 3Updated Jul 13, 2026
Sponsor: Hoffmann-La Roche
Moderately to Severely Active Crohns Disease
Australia, Taiwan, Thailand, United Kingdom
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerRecruiting
NCT07100106Phase 1, Phase 2Updated Jul 13, 2026
Sponsor: Genentech, Inc.
Breast Cancer
United States, Australia, Brazil, Canada, China +5 more
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's DiseaseActive Not Recruiting
NCT03100149Phase 2Updated Jul 13, 2026
Sponsor: Hoffmann-La Roche
Parkinson's Disease
United States, Austria, France, Germany, Spain
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruiting
NCT05789082Phase 1, Phase 2Updated Jul 13, 2026
Sponsor: Hoffmann-La Roche
Non-Small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +13 more
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes MellitusRecruiting
NCT06704672NAUpdated Jul 13, 2026
Sponsor: Hoffmann-La Roche
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Poland, Turkey (Türkiye)
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted InfectionsCompleted
NCT06369220NAUpdated Jul 13, 2026
Sponsor: Hoffmann-La Roche
Chlamydia Trachomatis Infection · Neisseria Gonorrhoeae Infection · Mycoplasma Genitalium Infection
United States
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruiting
NCT07405801Phase 2Updated Jul 13, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Brazil, Canada, France +7 more
A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart DiseaseRecruiting
NCT07495813Phase 1Updated Jul 13, 2026
Sponsor: Hoffmann-La Roche
Stable Coronary Artery Disease · Healthy Volunteers
Netherlands
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid TumorsActive Not Recruiting
NCT06537310Phase 1Updated Jul 13, 2026
Sponsor: Hoffmann-La Roche
Cancer-Neoplasms
Australia, Belgium, Canada, Denmark, Spain
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruiting
NCT05862285Phase 3Updated Jul 10, 2026
Sponsor: Hoffmann-La Roche
Cancer
Belgium, Canada, China, Costa Rica, France +9 more
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell LymphomaRecruiting
NCT06558604Phase 2Updated Jul 10, 2026
Sponsor: The Lymphoma Academic Research Organisation
Lymphoma, Mantle-Cell
Belgium, France
A Study of Risdiplam in Participants With Type I and Type II Spinal Muscle Atrophy (SMA)Not Yet Recruiting
NCT07531719N/AUpdated Jul 10, 2026
Sponsor: Hoffmann-La Roche
Spinal Muscle Atrophy
An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care TreatmentActive Not Recruiting
NCT06883240N/AUpdated Jul 10, 2026
Sponsor: Hoffmann-La Roche
Von Willebrand Disease, Type 3
United States, Belgium, Canada, Colombia, France +9 more
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaActive Not Recruiting
NCT04712097Phase 3Updated Jul 10, 2026
Sponsor: Hoffmann-La Roche
Relapsed or Refractory Follicular Lymphoma
United States, Australia, Brazil, China, France +10 more
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With AlectinibActive Not Recruiting
NCT04764188N/AUpdated Jul 10, 2026
Sponsor: Hoffmann-La Roche
NSCLC
Argentina, Australia, Austria, Belgium, Bulgaria +20 more
A Study of Giredestrant in Participants With Grade 1 Endometrial CancerActive Not Recruiting
NCT05634499Phase 2Updated Jul 10, 2026
Sponsor: Hoffmann-La Roche
Endometrial Cancer
United States, Canada, Italy, Poland

Previous page Next page